Injected gel might someday help treat heart failure

February 13, 2014 by Alan Mozes, Healthday Reporter
Injected gel might someday help treat heart failure
Early study of pigs found protective effect after heart attack.

(HealthDay)—Attempting to reduce the risk for heart failure following a heart attack, early research on swine takes a new protective approach: targeted injection of naturally occurring "protein inhibitors" directly into the heart.

The invasive procedure has only been attempted on adult pigs, whose hearts are considered comparable to that of humans.

But preliminary success in staving off failure in animal research already amounts to a "proof of concept," the investigators said, demonstrating that such a technique could work in people, too. And maybe even improve upon current oral medications.

Study co-author Dr. Francis Spinale, director of the Cardiovascular Translational Research Center at the University of South Carolina School of Medicine, described how heart attacks can lead to heart failure in humans.

"The heart is composed of four chambers, with the one that pumps oxygenated blood to the body termed the ," Spinale said. "[And] a change in the shape of the left ventricle is one of the key factors that physicians measure in patients following a heart attack."

The stress of a heart attack typically sends problematic tissue-destroying enzymes—known as "MMPs"— into overdrive, while at the same time blocking the activity of the body's helpful enzymes, known as "TIMPs," Spinale explained.

The result: a swelling of the left ventricle from football shape to basketball shape, followed by structural collapse, he said. This ultimately leads to heart failure, in which the heart loses the ability to pump sufficient blood throughout the body.

This worst-case scenario, Spinale said, is the drive behind his team's research: "to develop a strategy to restore the balance between MMPs and TIMPs in hopes of stopping this left ventricle remodeling process after a heart attack."

Spinale, who's also with Dorn Veteran Affairs Medical Center in Columbia, S.C., and colleagues published their findings in the Feb. 12 issue of Science Translational Medicine.

To reign in MMP activity, the investigators first combined a gelatin-type recipe containing hyaluronic acid with a slow-releasing compound of a specific TIMP called "TIMP-3."

Then, over a two-week period, the hearts of pigs that had been induced to have a heart attack were injected with either the TIMP-3/hydrogel mix or a non-medicinal saline solution.

In the weeks following a TIMP-3/hydrogel injection, the pigs that received it were found to have improved heart function, sidestepping the dangerous breakdown and reshaping of the heart's left ventricle.

The study team suggests that the new approach is a hopeful bet for human patients, given the similarity of pig and human heart anatomy, and previous indications that hydrogels can be safely injected into the human heart.

Experts note, however, that research with animals often fails to provide similar results in humans.

Dr. Nieca Goldberg, an American Heart Association spokeswoman, said it remains to be seen just how effective the new hydrogel treatment will prove to be in human patients.

"It's very important to talk about the fact that this is an animal study, which means that it's not yet ready for prime time. But certainly this is promising research," said Goldberg, medical director of the women's heart program at NYU Langone Medical Center, in New York City.

"We're always looking for ways that we can avoid damage to the heart muscle after a ," she said. "Right now we use [medications such as] ACE inhibitors and beta blockers to prevent heart failure. Before those came on board as options, more people had heart failure as a result of their heart attacks than is the case today.

"So this approach should be seen as another idea, an interesting therapy for the future, that may help us continue to bring risk further under control," Goldberg said.

Explore further: Researchers find comparable long-term outcomes between diastolic and systolic heart failure patients

More information: Paper: "Local Hydrogel Release of Recombinant TIMP-3 Attenuates Adverse Left Ventricular Remodeling After Experimental Myocardial Infarction," by S.R. Eckhouse et al. Science Translational Medicine, 2014.

To learn more about heart failure, visit the American Heart Association.

Related Stories

Researchers find comparable long-term outcomes between diastolic and systolic heart failure patients

January 9, 2014
A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly ...

Patients with heart failure need specialist care

November 1, 2013
(Medical Xpress)—New research from Karolinska Institutet in Sweden shows that patients with heart failure have high mortality and often are undertreated. According to a study, published in the scientific periodical JACC, ...

New injectable hydrogel encourages regeneration, improves functionality after heart attack

February 20, 2013
University of California, San Diego bioengineers have demonstrated in a study in pigs that a new injectable hydrogel can repair damage from heart attacks, help the heart grow new tissue and blood vessels, and get the heart ...

Heart disease linked with dementia in older postmenopausal women

December 18, 2013
Heart disease may put older postmenopausal women at higher risk for decreased brain function such as dementia, according to new research in Journal of the American Heart Association.

Exercising more, sitting less reduces heart failure risk in men

January 21, 2014
Sitting for long periods increases heart failure risk in men, even for those who exercise regularly, according to new research published in the American Heart Association journal Circulation: Heart Failure.

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.